Detecting Drugs of Abuse Via Exhaled Breath Samples Using Differential Mobility Spectrometry
NCT ID: NCT05384470
Last Updated: 2025-05-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
32 participants
OBSERVATIONAL
2021-08-01
2024-08-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sublingual Dexmedetomidine for Treating Opioid Withdrawal
NCT05712707
Informational App Development for mHealth for Patient Self-Management of Opioid Use Disorder
NCT05859035
Developing and Testing the Opioid Rapid Response System
NCT04589676
Resonance Breathing Intervention Opioid Use Disorder
NCT05830773
Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5
NCT00000330
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
If such a method becomes available it can be used by law enforcement and in doctors' offices, hospital emergency rooms, ambulances and other government agencies, military bases and companies seeking to screen employees for drug abuse. Vox Biomedical proposes to develop a method for quantitatively detecting the presence of drugs in EB by means of Differential Mobility Spectrometry (DMS) developed at Draper Laboratories. DMS is a robust, datarich, ultra-trace, chemical detection technology that has been proven for numerous applications including air quality cabin monitoring on the International Space Station (ISS), chemical warfare agent detection, explosives detection, and drinking water analysis. Recently Draper has applied this device to breath analysis for the detection of lung diseases.
A clinical study is currently underway and initial results are promising. This project involves transferring this technology developed by Draper for lung infection detection to the detection of psychoactive drugs in exhaled breath. Phase I of the proposed program will investigate the DMS signatures of cannabinoids in the laboratory and defining the device's limits of detection. A small pilot study will also be performed to demonstrate feasibility for using breath analysis as a proxy for the concentration of cannabinoids in the blood.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exhaled Breath Samples
Quantitative detection of marijuana, morphine or fentanyl through exhaled breath
Marihuana
Two doses of marijuana given.
BID2 Instrument - breathalyzer
The commercial device that we will be testing is designed to detect breath cannabinoid concentrations utilizing Differential Mobility Spectrometry technology, and was developed by Draper, to detect a wide range of chemicals and organisms in breath. Differential Mobility Spectrometry (DMS) is a robust, data-rich, ultra-trace, chemical detection technology. Unlike gas chromatography mass spectroscopy (GCMS) systems that are large and expensive, DMS is small, portable (approximately the size of a shoe box) and is able to measure the presence of volatile organic compounds (VOC) at parts per trillion (ppt) detection levels. The participant will exhale into the device via a plastic tube and the breath sample will be analyzed in situ. The participant does not come in contact with the device itself-they will simply exhale into a tube via a disposable mouthpiece.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Marihuana
Two doses of marijuana given.
BID2 Instrument - breathalyzer
The commercial device that we will be testing is designed to detect breath cannabinoid concentrations utilizing Differential Mobility Spectrometry technology, and was developed by Draper, to detect a wide range of chemicals and organisms in breath. Differential Mobility Spectrometry (DMS) is a robust, data-rich, ultra-trace, chemical detection technology. Unlike gas chromatography mass spectroscopy (GCMS) systems that are large and expensive, DMS is small, portable (approximately the size of a shoe box) and is able to measure the presence of volatile organic compounds (VOC) at parts per trillion (ppt) detection levels. The participant will exhale into the device via a plastic tube and the breath sample will be analyzed in situ. The participant does not come in contact with the device itself-they will simply exhale into a tube via a disposable mouthpiece.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* In good physical and mental health (normal physical exam, ECG, blood and urine chemistries
* Absence of history or laboratory evidence of diabetes)
* Body Mass Index between 18-30,
* Inclusive Age 21-50 years (age will be verified by driver's license or other valid form of identification)
* Have a stable living situation with current postal address.
Exclusion Criteria
* Concurrent diagnosis of Axis 1 disorder be maintained on an antipsychotic or antidepressant medication
* Taking prescription medications except certain short-term anti-fungal agents and some topical creams for dermal condition
* Heavy alcohol drinkers (greater than 15 drinks per week)
* Tobacco use greater than 5 cigarettes per day
* History of major head trauma resulting in cognitive impairment or history of seizure disorder
* Heavy caffeine use (greater than 500 mg on a regular daily basis)
* Has active hepatitis and/or aspartate aminotransferase (AST), alanine aminotransferase (ALT)\> 3x the upper limit of normal
* For female participants, a positive pregnancy test.
21 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
VOX BIOMEDICAL LLC
UNKNOWN
Mclean Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Scott Lukas
Director, McLean Imaging Center and BPRL
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
McLean Hospital
Belmont, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019P001633
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.